Cargando…

A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats

The potency of newly developed bispyridinium compounds (K117, K127) to reduce tabun-induced acute neurotoxic signs and symptoms was compared with currently available oxime (obidoxime) using functional observational battery. The neuroprotective effects of atropine alone and atropine combined with one...

Descripción completa

Detalles Bibliográficos
Autores principales: Kassa, Jiri, Karasova, Jana Zdarova, Musilek, Kamil, Kuca, Kamil, Jung, Young-Sik
Formato: Texto
Lenguaje:English
Publicado: Informa Healthcare 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736538/
https://www.ncbi.nlm.nih.gov/pubmed/19730756
http://dx.doi.org/10.1080/15376510802455362
_version_ 1782171346015354880
author Kassa, Jiri
Karasova, Jana Zdarova
Musilek, Kamil
Kuca, Kamil
Jung, Young-Sik
author_facet Kassa, Jiri
Karasova, Jana Zdarova
Musilek, Kamil
Kuca, Kamil
Jung, Young-Sik
author_sort Kassa, Jiri
collection PubMed
description The potency of newly developed bispyridinium compounds (K117, K127) to reduce tabun-induced acute neurotoxic signs and symptoms was compared with currently available oxime (obidoxime) using functional observational battery. The neuroprotective effects of atropine alone and atropine combined with one of three bispyridinium oximes (K117, K127, obidoxime) on rats poisoned with tabun at a sublethal dose (180 μg/kg i.m.; 80% of LD(50) value) were studied. Tabun-induced neurotoxicity was monitored using a functional observational battery and automatic measurement of motor activity at 24 h following tabun challenge. The results indicated that all tested oximes combined with atropine enabled tabun-poisoned rats to survive 24 h following tabun challenge while one tabun-poisoned rats died within 24 h after tabun poisoning when the rats were treated with atropine alone. Newly developed oxime K127 combined with atropine was the most effective in decreasing tabun-induced neurotoxicity in the case of sublethal poisonings among all oximes tested. Nevertheless, the differences of neuroprotective efficacy between K127 and obidoxime are not sufficient to replace obidoxime by K127 for the treatment of acute tabun poisonings.
format Text
id pubmed-2736538
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Informa Healthcare
record_format MEDLINE/PubMed
spelling pubmed-27365382009-09-02 A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats Kassa, Jiri Karasova, Jana Zdarova Musilek, Kamil Kuca, Kamil Jung, Young-Sik Toxicol Mech Methods Research Article The potency of newly developed bispyridinium compounds (K117, K127) to reduce tabun-induced acute neurotoxic signs and symptoms was compared with currently available oxime (obidoxime) using functional observational battery. The neuroprotective effects of atropine alone and atropine combined with one of three bispyridinium oximes (K117, K127, obidoxime) on rats poisoned with tabun at a sublethal dose (180 μg/kg i.m.; 80% of LD(50) value) were studied. Tabun-induced neurotoxicity was monitored using a functional observational battery and automatic measurement of motor activity at 24 h following tabun challenge. The results indicated that all tested oximes combined with atropine enabled tabun-poisoned rats to survive 24 h following tabun challenge while one tabun-poisoned rats died within 24 h after tabun poisoning when the rats were treated with atropine alone. Newly developed oxime K127 combined with atropine was the most effective in decreasing tabun-induced neurotoxicity in the case of sublethal poisonings among all oximes tested. Nevertheless, the differences of neuroprotective efficacy between K127 and obidoxime are not sufficient to replace obidoxime by K127 for the treatment of acute tabun poisonings. Informa Healthcare 2009-06-30 2009-03 /pmc/articles/PMC2736538/ /pubmed/19730756 http://dx.doi.org/10.1080/15376510802455362 Text en © 2009 Informa UK Ltd http://creativecommons.org/licenses/by/2.0/ This is an open access article distributed under the Supplemental Terms and Conditions for iOpenAccess articles published in Informa Healthcare journals (http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kassa, Jiri
Karasova, Jana Zdarova
Musilek, Kamil
Kuca, Kamil
Jung, Young-Sik
A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats
title A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats
title_full A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats
title_fullStr A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats
title_full_unstemmed A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats
title_short A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats
title_sort comparison of the neuroprotective efficacy of newly developed oximes (k117, k127) and currently available oxime (obidoxime) in tabun-poisoned rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736538/
https://www.ncbi.nlm.nih.gov/pubmed/19730756
http://dx.doi.org/10.1080/15376510802455362
work_keys_str_mv AT kassajiri acomparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats
AT karasovajanazdarova acomparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats
AT musilekkamil acomparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats
AT kucakamil acomparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats
AT jungyoungsik acomparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats
AT kassajiri comparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats
AT karasovajanazdarova comparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats
AT musilekkamil comparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats
AT kucakamil comparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats
AT jungyoungsik comparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats